Title |
ST6Gal-I sialyltransferase confers cisplatin resistance in ovarian tumor cells
|
---|---|
Published in |
Journal of Ovarian Research, April 2013
|
DOI | 10.1186/1757-2215-6-25 |
Pubmed ID | |
Authors |
Matthew J Schultz, Amanda F Swindall, John W Wright, Elizabeth S Sztul, Charles N Landen, Susan L Bellis |
Abstract |
Platinum drugs, including cisplatin, are a frontline therapeutic in ovarian cancer treatment and acquired resistance to these agents is a major contributor to ovarian cancer morbidity and mortality. In this study a novel glycosylation-dependent mechanism for cisplatin resistance is described. Specifically, cisplatin-induced cell death is blocked by the activity of the ST6Gal-I sialyltransferase. ST6Gal-I modifies specific receptors by adding a negatively charged sialic acid sugar which influences diverse receptor functions. Overexpression of ST6Gal-I is a hallmark of ovarian and other cancers and its expression has been correlated to metastasis and poor prognosis. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Central African Republic | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 3% |
Unknown | 58 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 11 | 18% |
Researcher | 11 | 18% |
Student > Master | 8 | 13% |
Student > Bachelor | 7 | 12% |
Student > Doctoral Student | 5 | 8% |
Other | 7 | 12% |
Unknown | 11 | 18% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 13 | 22% |
Medicine and Dentistry | 10 | 17% |
Agricultural and Biological Sciences | 10 | 17% |
Chemistry | 7 | 12% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 5% |
Other | 5 | 8% |
Unknown | 12 | 20% |